Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
Alzheimer’s disease
Cerebrospinal fluid
Incremental diagnostic value
Mild cognitive impairment
Positron emission tomography
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
22
04
2019
accepted:
26
07
2019
pubmed:
8
8
2019
medline:
15
5
2021
entrez:
8
8
2019
Statut:
ppublish
Résumé
To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence. EudraCT no.: 2014-005389-31.
Identifiants
pubmed: 31388720
doi: 10.1007/s00259-019-04466-6
pii: 10.1007/s00259-019-04466-6
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
tau Proteins
0
Banques de données
EudraCT
['2014-005389-31']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-280Références
Alzheimers Dement. 2015 Aug;11(8):964-74
pubmed: 25824567
Alzheimers Dement. 2018 Mar;14(3):293-305
pubmed: 29107051
J Alzheimers Dis. 2011;26(4):627-45
pubmed: 21694448
Neurodegener Dis. 2016;16(1-2):111-7
pubmed: 26618706
JAMA. 2009 Jul 22;302(4):385-93
pubmed: 19622817
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Lancet Neurol. 2011 May;10(5):424-35
pubmed: 21481640
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
J Alzheimers Dis. 2018;63(2):783-796
pubmed: 29689725
J Alzheimers Dis. 2012;31(1):13-20
pubmed: 22495345
J Alzheimers Dis. 2014;41(2):377-86
pubmed: 24614902
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Lancet Neurol. 2007 Aug;6(8):734-46
pubmed: 17616482
JAMA Neurol. 2018 Sep 1;75(9):1062-1070
pubmed: 29889941
Arch Neurol. 1975 Sep;32(9):632-7
pubmed: 1164215
Alzheimers Dement. 2019 Mar;15(3):388-399
pubmed: 30339801
Alzheimers Dement. 2013 May;9(3):251-61
pubmed: 23622690
Ann Neurol. 2013 Dec;74(6):826-36
pubmed: 23536396
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1276-1286
pubmed: 30915522
Lancet Neurol. 2017 Aug;16(8):661-676
pubmed: 28721928
Neurobiol Aging. 2017 Apr;52:214-227
pubmed: 28317650
Neurology. 2015 Oct 6;85(14):1240-9
pubmed: 26354982
Lancet. 2006 Jul 29;368(9533):387-403
pubmed: 16876668
Alzheimers Dement. 2013 Mar;9(2):137-40
pubmed: 23274154
Alzheimers Dement. 2013 Jul;9(4):414-21
pubmed: 23164552
World J Biol Psychiatry. 2018 Jun;19(4):244-328
pubmed: 29076399
J Alzheimers Dis. 2016 Oct 18;54(4):1297-1302
pubmed: 27567830
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15
pubmed: 23203162
JAMA. 2015 May 19;313(19):1939-49
pubmed: 25988463
J Nucl Med. 2017 Nov;58(11):1711-1717
pubmed: 28818990
J Alzheimers Dis. 2016 Apr 18;52(4):1251-62
pubmed: 27104896
Int J Alzheimers Dis. 2012;2012:548157
pubmed: 23326754
JAMA Neurol. 2015 Oct;72(10):1124-31
pubmed: 26302353